VA's Psilocybin Trial Is a Win, But Independent Research Still Faces Hurdles

October 1, 2026

Photo via Pexels.

Buried in the VA's press materials about a new psilocybin trial for veterans is a quieter story about who gets to do psychedelic research in this country and who doesn't. The Department of Veterans Affairs just launched a study dosing veterans with treatment-resistant depression using a synthetic, pharmaceutical-grade psilocybin formulation, and that's worth celebrating on its own terms. Veterans with depression that hasn't responded to SSRIs, therapy, or ketamine have been waiting a long time for anyone in a position of federal authority to take this seriously.

But the same federal apparatus applauding this trial still keeps psilocybin on Schedule I nationally, right alongside heroin, with no FDA-approved product on the market anywhere in the country. That contradiction isn't just a legal technicality for policy wonks to note in passing. It creates a structural gap that determines, in practice, who can run a psilocybin study and who can't. Well-resourced institutions like VA, with in-house counsel, federal security clearances, and decades of experience navigating DEA registration, can thread the needle. Independent researchers, university labs without deep pockets, and nonprofits working on shoestring budgets mostly can't. The VA's progress is real. It's just not evenly distributed, and that unevenness is worth examining closely.

Inside the PIVOT Trial

Photo via Pexels.

The trial is formally called the Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression study, shortened mercifully to PIVOT. It began recruiting on August 3, 2026, and is registered on ClinicalTrials.gov under identifier NCT07226232, where its status currently reads as actively recruiting. That means veterans interested in participating, or clinicians curious about referral criteria, can look up enrollment details directly rather than relying on secondhand summaries.

PIVOT is running across five VA sites, chosen presumably for existing research infrastructure and mental health staffing: Birmingham VA Health Care System and Tuscaloosa VA Medical Center in Alabama, VA Puget Sound Health Care System in Seattle, VA Portland Health Care System, and the Corporal Michael J. Crescenz VA Medical Center in Philadelphia. That geographic spread covers both coasts and the South, which should help with recruitment diversity and give the data broader applicability than a single-site study would.

The compound being tested is COMP360, a synthetic, pharmaceutical-grade psilocybin formulation manufactured by Compass Pathways and donated for the trial. Researchers are testing two different dosage levels against each other, standard practice for dose-finding work in psychedelic trials where the therapeutic window and side effect profile both matter enormously. What's striking is the timeline: primary completion isn't estimated until December 2030, with full study completion pushed to June 2031. That's a five-year runway, longer than most people following psychedelic research headlines probably expect, and a reminder that rigorous clinical trial work moves slowly even when political will is present.

VA Secretary Doug Collins framed the study as part of a broader commitment to pursue every available avenue for veterans whose depression simply hasn't responded to anything else tried so far. That's a notably open-ended way for a federal official to describe a Schedule I substance, and it signals how much the institutional posture toward psychedelics has shifted even within a single department.

A Broader Federal Push on Psychedelics

Photo via Pexels.

PIVOT isn't a standalone experiment. It's the VA's 20th active clinical trial exploring psychedelic-assisted therapies, a number that would have been unthinkable within the department a decade ago. The VA's Office of Research and Development has distributed more than $23 million in external funding to support this research pipeline, money flowing toward studies on MDMA, ketamine, ibogaine and psilocybin across multiple indications, not just depression.

This expansion didn't happen in isolation. It follows a memorandum of understanding signed July 13, 2026, between VA Secretary Doug Collins and HHS Secretary Robert F. Kennedy Jr., implementing Executive Order 14401 from the Trump administration. That order does several concrete things worth naming individually: it directs the FDA to issue priority review vouchers for qualifying psychedelic therapies, expands right-to-try access specifically for ibogaine, dedicates $50 million in ARPA-H funding toward psychedelic medicine research, and instructs the DEA to speed up scheduling decisions once the FDA approves a psychedelic product.

Taken together, this represents a genuinely unusual convergence. Veteran advocacy groups, who have been pushing psychedelic access for years on the grounds that conventional PTSD and depression treatments are failing too many service members, now find themselves aligned with an administration that campaigned on very different cultural signals than you'd typically expect to produce this kind of policy. Whatever the political calculus behind it, the practical effect is a federal government suddenly moving faster on psychedelic research infrastructure than it has in fifty years. That's worth acknowledging plainly, even while asking who benefits from it and who's left out.

The Catch: Schedule I Still Rules the Lab

Photo via Pexels.

Here's where the celebration needs a caveat. Psilocybin remains a Schedule I controlled substance federally, meaning the DEA's official position is that it has no currently accepted medical use and a high potential for abuse. No FDA-approved psilocybin product exists as of this writing, VA trial notwithstanding. That status hasn't moved, even as the executive branch pours tens of millions into studying the compound.

What that means practically is that any researcher wanting to work with psilocybin, VA-affiliated or not, must separately register with the DEA as a Schedule I manufacturer or distributor under 21 CFR Part 1301. This is a completely distinct process from FDA approval, with its own paperwork, its own security requirements, and its own timeline, running in parallel rather than in sequence. A sponsor can clear every single FDA hurdle, including Breakthrough Therapy designation, and still find itself unable to dose a single patient because the DEA registration, the mandated security vault, or the chain-of-custody documentation isn't in place yet.

The Usona Institute is the clearest illustration of how long this bottleneck can stretch. Usona received FDA Breakthrough Therapy designation for psilocybin in major depressive disorder back in 2019. Seven years later, there's still no filed New Drug Application. That's not necessarily evidence of bad faith or incompetence on Usona's part; it's evidence of how much infrastructure, legal capacity, and sustained capital a Schedule I research program demands, year after year, before it produces a filing.

That burden lands hardest on exactly the researchers least equipped to carry it: independent labs, university-affiliated investigators, and nonprofits without VA-level legal teams, dedicated security infrastructure, or federal backing to absorb years of regulatory friction.

States and Congress Are Filling the Gap

Photo via Pexels.

Lawmakers at both the federal and state level seem to recognize this imbalance, even if nobody's calling it that directly. Senate Bill 4031, introduced in March 2026, would require the VA to establish at least five innovative therapies centers of excellence dedicated to studying MDMA, ibogaine, ketamine and psilocybin. The bill proposes $30 million appropriated annually to fund both research and clinician education at those centers. As of this writing it's still pending, with no guarantee of passage, but its existence signals that Congress sees the current research capacity as insufficient even with PIVOT and nineteen other active VA trials underway.

California didn't wait around for Congress. Governor Gavin Newsom signed AB 113 around September 2026, directing $4.7 million specifically toward psilocybin, MDMA and ketamine research aimed at veterans with treatment-resistant PTSD. It's a fraction of the federal ARPA-H allocation, but it's state money moving independently of federal scheduling constraints, built around partnerships that don't require the same DEA registration burden a standalone independent lab would face alone.

Read together, SB 4031 and AB 113 suggest something important: the appetite for psychedelic research, among veterans' advocates, state legislators, and apparently even members of Congress willing to put bill numbers on paper, is outpacing what the existing Schedule I framework can efficiently accommodate. Centers of excellence and dedicated state funding are workarounds, not fixes. They route around the bottleneck instead of removing it. That's a reasonable short-term strategy, but it leaves the underlying structural problem, researchers outside these funded centers still facing the same DEA registration wall, completely untouched.

None of this changes what's legal for you to do with psilocybin today, wherever you're reading this from. VA trials and state research appropriations operate within carefully carved-out regulatory lanes; they don't rewrite federal drug law, and they don't decriminalize anything for people outside those specific programs. Psilocybin's legal status still varies enormously depending on context, state, and whether you're talking about a clinical trial, a decriminalization ordinance, or straightforward possession law, and it remains federally restricted everywhere in the US regardless of what any individual state has done.

If you're following this space because you or someone you know is a veteran considering treatment-resistant depression options, or you're just tracking where psychedelic policy is headed, the responsible move is checking your own state's current rules rather than assuming VA progress has quietly changed personal legality somewhere. Oregon and Colorado have built regulated access models; most other states haven't, and federal law still sits above all of it. The PIVOT trial is a meaningful step for the veterans who qualify and enroll. It's not a signal that the broader legal landscape has shifted, and treating it that way would be a mistake worth avoiding.